Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ChemGenex's Phantom Expanded Access Program For Omapro Cited By FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

DDMAC says that there is no expanded access program for the unapproved leukemia drug Omapro (omacetaxine mepesuccinate), but even if there were one, ChemGenex would not be allowed to promote it.

You may also be interested in...



IND Promotion Quandary Again Trips Up Burzynski Research Institute

The institute has come under scrutiny in the past for how it describes its investigational cancer products, but more mainstream oncology companies have also been cited for jumping the gun with promotional claims for products FDA hasn’t yet approved.

Cancer Drug Website Draws FDA's Ire For Promoting A Product In Clinical Trials

Keryx Biopharmaceuticals is cited for claiming on its website that its investigational oncology drug perifosine is safe and effective.

Cancer Drug Website Draws FDA's Ire For Promoting A Product In Clinical Trials

Keryx Biopharmaceuticals is cited for claiming on its website that its investigational oncology drug perifosine is safe and effective.

Related Content

Topics

UsernamePublicRestriction

Register

PS072212

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel